According to the administration of Podolsk Municipal District, the Ministry of Investments and Innovations of the Moscow Region has approved a list of 16 systemically important enterprises that have significant socio-economic and strategic significance for the manufacturing sector of Podolsk.
In 2016, despite the difficulties, the systemically important enterprises have overall demonstrated a trend of growth in production output. CJSC ZiO-Zdorovie became one of the leaders in terms of output volume (111.9%).
In 2017, CJSC ZiO-Zdorovie will continue technical re-equipment and modernization of its production facilities. Following the investment of 1.2 billion rubles, CJSC ZiO-Zdorovie plans to complete the construction of the second building this November, which will result in the creation of 186 new jobs. In 2017, the company will start the full cycle of manufacturing the pharmaceutical drugs of Astellas, a Japanese company.
As reported by the press service of CJSC ZiO-Zdorovie, on February 1, 2017, the company commissioned a Sampling Room equipped with KAPPA MINI3 laminar flow module. This is the first constructed object which is a part of currently being implemented CJSC ZiO-Zdorovie investment project for the construction of the second stage of the plant for the production of medicines. The Sampling Room has been designed and built in compliance with all key international standards and GMP rules. The total cost of the Sampling Room is 10 million rubles.